Focus Partners Advisor Solutions LLC Raises Stock Holdings in Ironwood Pharmaceuticals, Inc. $IRWD

Focus Partners Advisor Solutions LLC increased its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 284.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,743 shares of the biotechnology company’s stock after buying an additional 29,409 shares during the period. Focus Partners Advisor Solutions LLC’s holdings in Ironwood Pharmaceuticals were worth $29,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Armistice Capital LLC lifted its position in shares of Ironwood Pharmaceuticals by 44.7% in the first quarter. Armistice Capital LLC now owns 13,700,000 shares of the biotechnology company’s stock valued at $20,139,000 after acquiring an additional 4,232,000 shares in the last quarter. Millennium Management LLC lifted its holdings in Ironwood Pharmaceuticals by 186.6% in the 1st quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company’s stock valued at $9,349,000 after purchasing an additional 4,140,439 shares in the last quarter. Jane Street Group LLC lifted its holdings in Ironwood Pharmaceuticals by 740.5% in the 1st quarter. Jane Street Group LLC now owns 3,510,117 shares of the biotechnology company’s stock valued at $5,160,000 after purchasing an additional 3,092,475 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Ironwood Pharmaceuticals by 33.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,647,015 shares of the biotechnology company’s stock valued at $3,891,000 after purchasing an additional 663,775 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in Ironwood Pharmaceuticals by 160.7% in the 1st quarter. Acadian Asset Management LLC now owns 2,645,189 shares of the biotechnology company’s stock valued at $3,878,000 after purchasing an additional 1,630,726 shares in the last quarter.

Ironwood Pharmaceuticals Price Performance

Shares of IRWD stock opened at $1.92 on Monday. The firm’s 50-day moving average is $1.42 and its two-hundred day moving average is $1.00. Ironwood Pharmaceuticals, Inc. has a 12 month low of $0.53 and a 12 month high of $5.13. The company has a market capitalization of $311.87 million, a PE ratio of -38.39 and a beta of 0.30.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its earnings results on Thursday, August 7th. The biotechnology company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.16. The company had revenue of $85.24 million for the quarter, compared to the consensus estimate of $62.02 million. Ironwood Pharmaceuticals had a negative net margin of 2.25% and a negative return on equity of 2.46%. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on IRWD shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Ironwood Pharmaceuticals in a research note on Wednesday, October 8th. Zacks Research raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 6th. Finally, Wall Street Zen raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 9th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $4.94.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.